Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...

Precision BioSciences, Inc.’s DTIL share price has dipped by 9.90%, which has investors questioning if this is right time to ...

DURHAM, N.C. (AP) — DURHAM, N.C. (AP) — Precision BioSciences Inc. (DTIL) on Thursday reported a loss of $20.6 million in its first quarter. On a per-share basis, the Durham, North Carolina-based ...

Analysts estimate that Precision BioSciences will report an earnings per share (EPS) of $-2.42. Precision BioSciences bulls ...

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -413.95% and 99.71%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock ...

Chief Executive Officer of Precision BioSciences. “In addition, the Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV, our lead program for chronic Hepatitis B, is progressing as planned.

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...

Precision BioSciences (NASDAQ:DTIL) is scheduled to announce Q1 earnings results on Thursday, May 15th, before market open. The consensus EPS Estimate is -$2.42 (-242.4% Y/Y) and the consensus Revenue ...

Precision BioSciences (NASDAQ:DTIL) is scheduled to announce Q1 earnings results on Thursday, May 15th, before market open. The consensus EPS Estimate is -$2.42 (-242.4% Y/Y) and the consensus ...

Precision BioSciences (DTIL) came out with a quarterly loss of $2.21 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.35 per share a year ago.